Arm sore; Arm hardened; pustule at vaccine site; injection site darkened; injection site peeling, scaly; vaccination site  redness; raw skin; swollen wrist; pain in wrist; couldn't sleep; This spontaneous case was reported by a health care professional and describes the occurrence of MYALGIA (Arm sore), INDURATION (Arm hardened), PUSTULE (pustule at vaccine site), SKIN DISCOLOURATION (injection site darkened) and SKIN EXFOLIATION (injection site peeling, scaly) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014M20A and 047A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Arthritis, COPD, Glaucoma, Posttraumatic stress disorder and Back disorder. Concomitant products included TELMISARTAN (MICARDIS), CELECOXIB (CELEBREX), GABAPENTIN, LAMOTRIGINE (LAMICTAL), ATORVASTATIN, LANSOPRAZOLE (PREVACID), HYDROCHLOROTHIAZIDE, MONTELUKAST, BRIMONIDINE TARTRATE, TIMOLOL MALEATE (COMBIGAN), BRIMONIDINE TARTRATE, TIMOLOL MALEATE (COMBIGAN), TIOTROPIUM BROMIDE (SPIRIVA), FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR), ALPRAZOLAM, Multivitamins                                                  Once daily, VITAMIN B12 (VITAMIN B12 (CYANOCOBALAMIN AND ANALOGUES)), COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]), COLECALCIFEROL, UBIDECARENONE (COQ10 + D3) and BIOTIN for an unknown indication.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (Arm sore), INDURATION (Arm hardened), PUSTULE (pustule at vaccine site), SKIN DISCOLOURATION (injection site darkened), SKIN EXFOLIATION (injection site peeling, scaly), VACCINATION SITE ERYTHEMA (vaccination site  redness), SKIN EROSION (raw skin), JOINT SWELLING (swollen wrist), ARTHRALGIA (pain in wrist) and INSOMNIA (couldn't sleep). The patient was treated with CELECOXIB (CELEBREX) at a dose of 3000 mg in one day; ACETAMINOPHEN at a dose of 3000 mg in one day and NEOMYCIN, POLYMYXIN B SULFATE, PRAMOCAINE HYDROCHLORIDE (NEOSPORE P.R.) for Pustule, at an unspecified dose and frequency. At the time of the report, MYALGIA (Arm sore), INDURATION (Arm hardened), PUSTULE (pustule at vaccine site), SKIN DISCOLOURATION (injection site darkened), SKIN EXFOLIATION (injection site peeling, scaly), VACCINATION SITE ERYTHEMA (vaccination site  redness), SKIN EROSION (raw skin), JOINT SWELLING (swollen wrist), ARTHRALGIA (pain in wrist) and INSOMNIA (couldn't sleep) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment ;First Dose: Ice pack on the injections site (on and off for 48 hours)   This case was linked to US-MODERNATX, INC.-MOD-2021-071456 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 27-May-2021: AE contact information updated and verified with consumer; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-071456:First dose case